Cancers (Jul 2024)

VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma

  • Natalia Muñoz Perez,
  • Juliana M. Pensabene,
  • Phillip M. Galbo,
  • Negar Sadeghipour,
  • Joanne Xiu,
  • Kirsten Moziak,
  • Rita M. Yazejian,
  • Rachel L. Welch,
  • W. Robert Bell,
  • Soma Sengupta,
  • Sonikpreet Aulakh,
  • Charles G. Eberhart,
  • David M. Loeb,
  • Emad Eskandar,
  • Deyou Zheng,
  • Xingxing Zang,
  • Allison M. Martin

DOI
https://doi.org/10.3390/cancers16152629
Journal volume & issue
Vol. 16, no. 15
p. 2629

Abstract

Read online

Background: Relapsed medulloblastoma (MB) poses a significant therapeutic challenge due to its highly immunosuppressive tumor microenvironment. Immune checkpoint inhibitors (ICIs) have struggled to mitigate this challenge, largely due to low T-cell infiltration and minimal PD-L1 expression. Identifying the mechanisms driving low T-cell infiltration is crucial for developing more effective immunotherapies. Methods: We utilize a syngeneic mouse model to investigate the tumor immune microenvironment of MB and compare our findings to transcriptomic and proteomic data from human MB. Results: Flow cytometry reveals a notable presence of CD45hi/CD11bhi macrophage-like and CD45int/CD11bint microglia-like tumor-associated macrophages (TAMs), alongside regulatory T-cells (Tregs), expressing high levels of the inhibitory checkpoint molecule VISTA. Compared to sham control mice, the CD45hi/CD11bhi compartment significantly expands in tumor-bearing mice and exhibits a myeloid-specific signature composed of VISTA, CD80, PD-L1, CTLA-4, MHCII, CD40, and CD68. These findings are corroborated by proteomic and transcriptomic analyses of human MB samples. Immunohistochemistry highlights an abundance of VISTA-expressing myeloid cells clustering at the tumor–cerebellar border, while T-cells are scarce and express FOXP3. Additionally, tumor cells exhibit immunosuppressive properties, inhibiting CD4 T-cell proliferation in vitro. Identification of VISTA’s binding partner, VSIG8, on tumor cells, and its correlation with increased VISTA expression in human transcriptomic analyses suggests a potential therapeutic target. Conclusions: This study underscores the multifaceted mechanisms of immune evasion in MB and highlights the therapeutic potential of targeting the VISTA–VSIG axis to enhance anti-tumor responses.

Keywords